Form 4: Cytokinetics Director Acquires Shares in Lieu of Cash Retainer

Director Robert Arthur Harrington acquired 228 shares of Cytokinetics Inc. common stock on July 1, 2024, as a stock award in lieu of a cash retainer payment.

Summary

• On July 1, 2024, Robert Arthur Harrington, a director of Cytokinetics Inc., acquired 228 shares of common stock.
• The acquisition was a stock award made in lieu of a cash retainer payment.
• Following the transaction, Harrington beneficially owns 15,769 shares of Cytokinetics Inc.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard transaction. The director taking stock instead of cash is a mildly positive signal.

Positives

• The director's acceptance of stock in lieu of cash may signal confidence in the company's future prospects.

Industry Context

Directors receiving stock in lieu of cash compensation is a fairly common practice, particularly in biotech companies, to conserve cash and align director interests with shareholder value.

Stakeholder Impact

• The acceptance of stock in lieu of cash compensation by a director could be viewed positively by shareholders as it aligns the director's interests with the company's stock performance.

Key Dates